Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (Captem) in Patients with Metastatic Neuroendocrine Tumors (NETS). A Single-Institution Experience

被引：0
|
作者：
Smiroldo, V [1 ]
Carnaghi, C. [1 ]
Lania, A. [1 ]
Bonifacio, C. [1 ]
Pepe, G. [1 ]
Zerbi, A. [1 ]
Rimassa, L. [1 ]
Lavezzi, E. [1 ]
Spaggiari, P. [1 ]
机构：
[1] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Rozzano, Italy
来源：
NEUROENDOCRINOLOGY | 2018年 / 106卷
关键词：
captem; metastatic neuroendocrine tumors;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H23
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [41] Temozolomide and capecitabine in the treatment of metastatic digestive neuroendocrine tumor: The experience of a single Portuguese cancer centre
    Joana, Carvalho
    Joao, Ribeiro
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [42] Chromogranin A (CgA) in the Diagnosis and Monitoring of Patients with Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NET): A Single-Institution Experience
    Massironi, S.
    Rossi, R. E.
    Spampatti, M. P.
    Casazza, G.
    Conte, D.
    Ciafardini, C.
    Cavalcoli, F.
    Peracchi, M.
    [J]. NEUROENDOCRINOLOGY, 2012, 96 : 48 - 48
  • [43] Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) 90Y-Dotatoc in Neuroendocrine Tumors (NETs) Patients: Single-Institution Retrospective Analysis
    Dioca, M. H.
    Ortega Chahla, E.
    Ciavarelli, I
    Macharashvili, I
    Cuartero, V
    Adur, A.
    Katz, L.
    Rojas Bilbao, E.
    Diaz, C.
    [J]. NEUROENDOCRINOLOGY, 2019, 108 : 209 - 209
  • [44] Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors
    Ingenerf, Maria
    Auernhammer, Christoph
    Lorbeer, Roberto
    Winkelmann, Michael
    Mansournia, Shiwa
    Mansour, Nabeel
    Hesse, Nina
    Heinrich, Kathrin
    Ricke, Jens
    Berger, Frank
    Schmid-Tannwald, Christine
    [J]. RADIOLOGY AND ONCOLOGY, 2024, 58 (02) : 196 - 205
  • [45] Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience
    Ambe, Chenwi M.
    Phuong Nguyen
    Centeno, Barbara A.
    Choi, Junsung
    Strosberg, Jonathan
    Kvols, Larry
    Hodul, Pamela
    Hoffe, Sarah
    Malafa, Mokenge P.
    [J]. CANCER CONTROL, 2017, 24 (05)
  • [46] Temozolomide in paediatric patients with recurrent CNS tumors: A single institution experience
    Ingrosso, A.
    Suraci, S.
    Clerico, A.
    Cappelli, C.
    [J]. BONE MARROW TRANSPLANTATION, 2008, 41 : S143 - S144
  • [47] Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
    Hwang, Eugene
    Lee, Hyo Jin
    Sul, Chong Koo
    Lim, Jae Sung
    [J]. KOREAN JOURNAL OF UROLOGY, 2010, 51 (07) : 450 - 455
  • [48] Salvage chemotherapy for advanced sarcoma patients: A single-institution experience survey
    Serrone, L
    Nardoni, C
    Gelibter, A
    Felici, A
    Cognetti, F
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2002, 21 (02): : 181 - 184
  • [49] Metronomic Temozolomide (mTMZ) and Bevacizumab-The Safe and Effective Frontier for Treating Metastatic Neuroendocrine Tumors (NETs): A Single-Center Experience
    Unal, Caglar
    Saglam, Sezer
    [J]. CANCERS, 2023, 15 (23)
  • [50] Maintenance therapy following first-line chemotherapy in metastatic colorectal cancer: toxicity and efficacy—single-institution experience
    Mikahil Fedyanin
    Alexey Tryakin
    Anna Vybarava
    Dzhennet Chekini
    Ilya Pokataev
    Olga Sekhina
    Sergey Gordeev
    Vechaslav Aliev
    Sergei Tjulandin
    [J]. Medical Oncology, 2015, 32
12345